Emerging drugs for urothelial (bladder) cancer

Cumberbatch, K. N.; He, Tianfang; Thorogood, Zachary; Gartrell, Benjamin A.

doi:10.1080/14728214.2017.1336536

Cited by 13 publications

(12 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although current therapies can achieve a good prognosis, approximately 40% of these patients will progress to muscle-invasive disease after 5 years. [2][3][4] Moreover, the 5-year survival rate of muscle-invasive BCa is only 60%. [5] The epidemiology of BCa exhibits obvious regional, sex, and age variations.…”

Section: Introductionmentioning

confidence: 99%

Global, regional, and national burdens of bladder cancer in 2017: estimates from the 2017 Global Burden of Disease study

Xie

Chen

et al. 2020

Preprint

View full text Add to dashboard Cite

Abstract Background The aim of this study is to describe the prevalence and mortality rates of bladder cancer (BCa) using data obtained in the Global Burden of Disease study performed in 2017 (GBD 2017). Methods Data on BCa for 2017, including prevalence, mortality, and disability-adjusted life years (DALYs), were obtained from GBD 2017 at the global, regional, and national levels. We also analyzed the association of BCa burden with the country development level. Results There were 2.63 million BCa cases estimated from the GBD 2017 data, with 200,000 persons dying of BCa, resulting in 3.60 million DALYs in 2017. The age-standardized prevalence rate (ASPR) of BCa was 32.91/100,000 persons, and age-standardized death rate (ASDR) was 2.57/100,000 persons. The ASPR and ASDR of BCa were higher in males than in females, and higher in people older than 60 years. The ASPR and ASDR of BCa were higher in Western Europe and Central Europe than in South Asia, Andean Latin America, and Central Latin America, and higher in countries with a higher sociodemographic index (SDI). Correlation analysis identified that the ASPR and ASDR of BCa were positively correlated with the country SDI (P < 0.0001 and ρ = 0.68 for ASPR, and P = 0.0048 and ρ = 0.20 for ASDR). Smoking was the main risk factors attributable to the BCa burden. Conclusion The prevalence and mortality rates of BCa were very high in 2017, especially in high-SDI countries. Smoking-cessation strategies should be strengthened to control the burden associated with BCa.

show abstract

Section: Introductionmentioning

confidence: 99%

Global, regional, and national burdens of bladder cancer in 2017: estimates from the 2017 Global Burden of Disease study

Xie

Chen

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Although current therapies can achieve a good prognosis, approximately 40% of these patients will progress to muscle-invasive disease after 5 years. [2][3][4] Moreover, the 5-year survival rate of muscle-invasive BCa is only 60%. [5] The burden of BCa exhibits obvious regional, sex, and age variations.…”

Section: Introductionmentioning

confidence: 99%

Global, regional, and national burdens of bladder cancer in 2017: estimates from the 2017 Global Burden of Disease study

Xie

Chen

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: The aim of this study is to describe the prevalence and mortality of bladder cancer (BCa) using data obtained in the Global Burden of Disease study performed in 2017 (GBD 2017).Methods: Data on BCa for 2017, including prevalence, mortality, and disability-adjusted life years (DALYs), were obtained from GBD 2017 at the global, regional, and national levels. We also analyzed the association of BCa burden with the country development level.Results: There were 2.63 million BCa cases estimated from the GBD 2017 data, with 200,000 persons dying of BCa, resulting in 3.60 million DALYs in 2017. The age-standardized prevalence (ASP) of BCa was 32.91/100,000 persons, and age-standardized death rate (ASDR) was 2.57/100,000 persons. The ASP and ASDR of BCa were higher in males than in females, and higher in people older than 60 years. The ASP and ASDR of BCa were higher in Western Europe and Central Europe than in South Asia, Andean Latin America, and Central Latin America, and higher in countries with a higher sociodemographic index (SDI). Correlation analysis identified that the ASP and ASDR of BCa were positively correlated with the country SDI (P<0.0001 and ρ=0.68 for ASP, and P=0.0048 and ρ=0.20 for ASDR). In addition, 33.72% deaths and 36.80% DALYs caused by BCa could be attributed to smoking globally.Conclusion: The prevalence and mortality of BCa were very high in 2017, especially in high-SDI countries. Smoking-cessation strategies should be strengthened to control the burden associated with BCa.

show abstract

“…Advanced/metastatic urothelial carcinoma (UC), including carcinomas arising in the bladder, urethra, ureter, and/or renal pelvis, has a poor prognosis. Median survival is approximately 12–14 months with standard first-line platinum-based chemotherapy for advanced/metastatic disease [ 1 ]. Despite approvals of various targeted therapies for platinum-refractory advanced UC, most patients have limited treatment options as they experience disease progression.…”

Section: Introductionmentioning

confidence: 99%

“…Ramucirumab (a human IgG1 monoclonal antibody and a VEGFR-2 antagonist) [ 9 , 10 ] plus docetaxel improved PFS (hazard ratio [HR] = 0.757; 95% confidence interval [CI] [0.607, 0.943]) compared with placebo plus docetaxel in the randomized phase 3 trial for platinum-refractory advanced UC (RANGE; NCT02426125) [ 2 ]. Whereas other antiangiogenic drugs have failed thus far in refractory UC [ 1 , 11 , 12 ]. Patients treated in the ramucirumab arm also had a numerically higher objective response rate (24.50%, 95% CI [18.80, 30.30] vs 14.0%, 95% CI [9.40, 18.60]) [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE)

et al. 2020

View full text Add to dashboard Cite

Background To evaluate patient-reported outcomes with ramucirumab plus docetaxel, a regimen which improved progression-free survival in platinum-refractory advanced urothelial carcinoma (aUC). Methods RANGE—a randomized, double-blinded, phase 3 trial in patients with platinum-refractory aUC. Ramucirumab (10 mg/kg) plus docetaxel (75 mg/m2) or placebo plus docetaxel were administered every 21 days until disease progression or unacceptable toxicity. Patients received maximum 10 cycles of docetaxel. European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) and EuroQoL five-dimensions (EQ-5D-5L) were administered at baseline, start of each cycle, and 30-day follow-up visit. A ≥ 10-point change in QLQ-C30 scores was considered meaningful. Rates of improved/stable scores were compared between treatment arms using Fisher’s exact test. Time to deterioration (TtD) was estimated and compared using Kaplan–Meier estimation and log-rank test. Results Of the 530 patients, ~ 97% patients in each arm provided baseline QLQ-C30 data. On-treatment compliance was ≥ 88% for first 8 cycles. Mean baseline QLQ-C30 scores were similar between arms, with global quality of life (QoL), fatigue, pain, and insomnia having greatest impairment. Postbaseline rates of improved/stable QLQ-C30 scores were similar between treatment arms except for greater improvement in pain score with ramucirumab. TtD of QLQ-C30 scales favored ramucirumab arm. Baseline EQ-5D-5L index and visual analogue scale scores were similar between arms, followed by relatively stable on-treatment scores. EQ-5D-5L scores worsened at post-discontinuation follow-up visit. Conclusions Ramucirumab plus docetaxel did not negatively impact QoL compared with docetaxel alone in platinum-refractory aUC. Improved TtD and tumor associated rates of pain favored ramucirumab treatment. Clinical trail registration NCT02426125. https://clinicaltrials.gov/ct2/show/NCT02426125. Date of registration: April 24th 2015

show abstract

Emerging drugs for urothelial (bladder) cancer

Cited by 13 publications

References 82 publications

Global, regional, and national burdens of bladder cancer in 2017: estimates from the 2017 Global Burden of Disease study

Global, regional, and national burdens of bladder cancer in 2017: estimates from the 2017 Global Burden of Disease study

Global, regional, and national burdens of bladder cancer in 2017: estimates from the 2017 Global Burden of Disease study

Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE)

Contact Info

Product

Resources

About